Načítá se...
Long-term surviving cancer patients as a source of therapeutic TCR
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with “natural” wild type TCRs. Indeed, th...
Uloženo v:
| Vydáno v: | Cancer Immunol Immunother |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Berlin Heidelberg
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183495/ https://ncbi.nlm.nih.gov/pubmed/31915853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-019-02468-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|